Non-Hodgkin Lymphoma Education
Non-Hodgkin lymphoma is the 7th most common cancer in the US, encompassing diverse subtypes each with distinct treatment paradigms. Knowledge Med sessions help physicians navigate the NHL landscape — from aggressive B-cell lymphomas to indolent subtypes — through interactive case simulations and real-time peer comparison.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing non-hodgkin lymphoma face evolving treatment decisions that interactive, independently reviewed education can help address.
- Classifying NHL subtypes accurately and selecting subtype-appropriate treatment
- Integrating bispecific antibodies and CAR-T cell therapy across multiple NHL subtypes
- Managing immune effector cell-associated toxicities (CRS, ICANS) across novel therapies
- Sequencing targeted agents, immunotherapy, and cellular therapy in relapsed disease
What Sessions Cover
Knowledge Med NHL sessions use interactive case simulations to address these topics and more.
- NHL subtype classification and initial treatment approach
- Bispecific antibodies across NHL: DLBCL, follicular, MCL, and marginal zone
- CAR-T cell therapy: cross-subtype patient selection and referral timing
- Novel agents reshaping the NHL treatment landscape
Interactive NHL Sessions
Case Simulations
Work through realistic non-hodgkin lymphoma patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key NHL clinical takeaways.
More Hematologic Malignancy Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Chronic Lymphocytic Leukemia
CLL / SLL — First-line therapy selection in CLL: BTK inhibitors vs venetoclax combinations
Diffuse Large B-Cell Lymphoma
DLBCL — Frontline DLBCL: pola-R-CHP and risk-adapted strategies
Multiple Myeloma
Frontline induction: triplet vs quadruplet therapy and transplant decisions
Acute Myeloid Leukemia
AML — Molecular-guided frontline therapy selection in AML
Join a NHL Session
Third-party, non-promotional non-hodgkin lymphoma education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session